Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial inections
AssigneeCorus Pharma, Inc.
InventorAlan Montgomery
Life of this patent
Estimating the term…
Abstract
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
Claims36
A method of treating pulmonary infections caused by gram-negative bacteria, said method comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof.
A method of treating infections caused by the gram-negative bacteria in patients with cystic fibrosis or bronchiectasis, or in patients on ventilators with pneumonia, comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam lysinate formulation comprises from about 1 to about 250 mg of aztreonam lysinate.
A method of treating pulmonary infections caused by gram-negative bacteria comprising delivering an aerosol of an inhalable aztreonam lysinate formulation to the lung endobronchial space of airways of a patient in need thereof, wherein the inhalable aztreonam formulation comprises from about 1 to about 250 mg of aztreonam lysinate dissolved in about 1 to about 5 ml of a saline solution.
An inhalable pharmaceutically acceptable composition comprising from about 1 to about 250 mg per one dose of aztreonam lysinate, said composition suitable for treatment of pulmonary bacterial infections caused by gram-negative bacteria wherein said aztreonam lysinate is prepared as an aerosolable saline solution.
An aerosol composition comprising from about 1 to about 250 mg of aztreonam lysinate, wherein said aztreonam lysinate is dissolved in from about 1 to about 5 ml of a saline solution containing from about 0.1 to about 0.9% sodium chloride.
Dependencies are inferred from the claim text.